Cyclic Peptide Ingredients TRIZ Cases
- Amatoxin-Linker Conjugates With 6-OH Trp for Solid Tumors
A 6-OH Trp amatoxin-linker boosts solid tumor cytotoxicity while cleavable antibody linkers balance targeted release and circulation stability.
- WS635 Oral Compound for Direct Wound Healing Promotion
An oral WS635 compound overcomes weak wound-care efficacy by inhibiting Cyclophilin D, promoting angiogenesis, and reducing wound area.
- OR4-Modified Amatoxin Conjugates for Solid Tumor Potency
Position-4 OR4 substitution and a cleavable linker boost amatoxin antibody conjugate release and cytotoxicity against solid tumors.
- Isocyclosporin A Salt Preparation via Microwave Transesterification
Microwave-assisted transesterification converts cyclosporin A into isocyclosporin A salt with higher yield, shorter synthesis time, and lower toxicity.
- NAB815 Compound for Low-Toxicity Shiga Toxin 2 Inhibition
Reduced-charge NAB815 blocks Shiga toxin 2 interaction with TLR4 at lower concentrations, helping treat HUS with less toxicity.
- Peptide–Surfactant Compositions for Membrane Permeability
Surfactants mediate peptide transport across membranes, improving permeability and absorbability without changing target binding.
- Cyclosporine Derivative–PLGA Composition for Stable Topical Release
Position 3 substitution and PLGA embedding address the initial burst, retaining cyclosporine locally for stable release over one to four weeks.
- Peptide–Surfactant Compositions for Membrane Permeability and Absorption
This case pairs selected peptide compounds with carnitine-residue surfactants to improve Caco-2 permeability and absorbability.
- Macrocyclic Peptide Formulations Using Salcaprozate for Oral Absorption
This case combines salcaprozate sodium, nicotinamide, and protease inhibitors to protect peptides and improve oral bioavailability.
- Whole-Blood Immunosuppressant Reagent for Centrifuge-Free Detection
A low-toxicity reagent combination releases bound immunosuppressants from whole blood for accurate immunoassay without centrifugation.
- Anti-IL-31 Antibody Detection with Species-Specific Mimotopes
Species-specific IL-31 mimotopes simplify anti-IL-31 antibody measurement and support vaccine development for atopic dermatitis.
- Zilucoplan PLGA Sustained Release Formulation
A sustained release formulation incorporating a C5 inhibitory cyclic polypeptide combined with a poly lactic-co-glycolic acid matrix.
- SMEDDS Pseudo-Ternary System for CRV431 Solubility
Self-microemulsifying drug delivery system enhances CRV431 solubility via pseudo-ternary phase formulation.
- BLVRB Inhibitors Without Xanthene Moieties for Platelet Count Increase
Compounds blocking Biliverdin reductase B binding sites increase platelet counts while avoiding cytotoxicity and multimerization of xanthene-based inhibitors.
- Self-Emulsifying Formulation for Peptide Membrane Permeability
Oleate-based self-emulsifying formulations bypass first-pass metabolism to increase bioavailability and absorption of hydrophobic compounds.
- Orthotopic Liver Transplantation Immune Tolerance via Mixed Chimerism
Establishing immune tolerance for liver allografts via bone marrow infusion to eliminate immunosuppressant complications.
- Amanitin Antibody Conjugate Plasma Stability
Cleavable linkers stabilize amanitin in blood plasma until endocytosis releases the toxin at target sites.
- Cyclic Arginine-Rich Peptides for Stable Antimicrobial Therapy
Modular cyclic structures enhance peptide stability and reduce inflammatory side effects while lowering production costs.
- Oral Melanocortin Agonist Bioavailability via Protease Inhibitors
Melanocortin receptor agonists combine with protease inhibitors and absorption enhancers to enable effective oral delivery of peptide drugs.
- Cyclosporin Derivatives Targeting Cyclophilins for Hepatitis
Cyclosporin derivatives bind host cyclophilins to block viral replication, reducing drug resistance in hepatitis treatment.
- DNA Oligonucleotide Therapeutic for Hunner-Type Interstitial Cystitis
A DNA oligonucleotide selectively binds to IFN-gamma to inhibit activity.
- PEG Solvent Biodegradable Polymer Depot Formulation
Replacing NMP with specific PEG grades resolves storage stability and toxicity trade-offs in injectable depot systems.